Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02340819
Recruitment Status : Completed
First Posted : January 19, 2015
Results First Posted : November 20, 2019
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
Takeda ( Shire )

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of an investigational treatment (teduglutide) in Japanese patients with PN-dependent SBS. This study will also look at how teduglutide moves through the body (pharmacokinetics).

Condition or disease Intervention/treatment Phase
Short Bowel Syndrome Drug: Teduglutide Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 4-Stage, Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome
Actual Study Start Date : December 18, 2014
Actual Primary Completion Date : November 5, 2018
Actual Study Completion Date : November 5, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Teduglutide

Arm Intervention/treatment
Experimental: Arm 1
0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
Drug: Teduglutide
0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.




Primary Outcome Measures :
  1. Stage 2: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24 [ Time Frame: Baseline (stage 2), Week 24 ]
    Absolute change from baseline in weekly PS volume at Week 24 was reported.

  2. Stage 2: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24 [ Time Frame: Baseline (stage 2), Week 24 ]
    Percent change from baseline in weekly PS volume at Week 24 was reported.

  3. Stage 2: Percentage of Participants Who Demonstrate Response to Teduglutide at End of Stage 2 [ Time Frame: End of Stage 2 (up to Week 24) ]
    Response was defined as the achievement of at least a 20% reduction from baseline (Visit 2) in weekly PS volume at Week 20 and again at Week 24.

  4. Stage 2: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Week 24 [ Time Frame: Baseline (stage 2), Week 24 ]
    Absolute change from baseline in number of days per Week of PS usage at Week 24 was reported.

  5. Stage 2: Absolute Change From Baseline in Plasma Citrulline Levels at Week 24 [ Time Frame: Baseline (stage 2), Week 24 ]
    Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at Week 24 was reported.

  6. Stage 2: Percent Change From Baseline in Plasma Citrulline Levels at Week 24 [ Time Frame: Baseline (stage 2), Week 24 ]
    Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at Week 24 was reported.

  7. Stage 2: Number of Participants Who Achieved Enteral Autonomy at Week 24 [ Time Frame: Week 24 ]
    Enteral autonomy was defined as no prescribed PS and no use of PS recorded in the participant diary at the end of stage 2. Number of participants who achieved enteral autonomy at Week 24 was reported.

  8. Stage 3: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24 [ Time Frame: Baseline (stage 3), Extension Month 24 ]
    Absolute change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

  9. Stage 3: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24 [ Time Frame: Baseline (stage 3), Extension Month 24 ]
    Percent change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

  10. Stage 3: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Extension Month 24 [ Time Frame: Baseline (stage 3), Extension Month 24 ]
    Absolute change from baseline in number of days per Week of PS usage at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

  11. Stage 3: Absolute Change From Baseline in Plasma Citrulline Levels at Extension Month 24 [ Time Frame: Baseline (stage 3), Extension Month 24 ]
    Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

  12. Stage 3: Percent Change From Baseline in Plasma Citrulline Levels at Extension Month 24 [ Time Frame: Baseline (stage 3), Extension Month 24 ]
    Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

  13. Stage 4: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment [ Time Frame: Baseline (stage 4), End of Treatment (up to 47 months) ]
    Absolute change from baseline in weekly PS volume at end of treatment was reported.

  14. Stage 4: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment [ Time Frame: Baseline (stage 4), End of Treatment (up to 47 months) ]
    Percent change from baseline in weekly PS volume at end of treatment was reported.

  15. Stage 4: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment [ Time Frame: Baseline (stage 4), End of Treatment (up to 47 months) ]
    Absolute change from baseline in number of days per week of PS usage at end of treatment was reported.

  16. Stage 4: Absolute Change From Baseline in Plasma Citrulline Levels at End of Treatment [ Time Frame: Baseline (stage 4), End of Treatment (up to 47 months) ]
    Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at end of treatment was reported.

  17. Stage 4: Percent Change From Baseline in Plasma Citrulline Levels at End of Treatment [ Time Frame: Baseline (stage 4), End of Treatment (up to 47 months) ]
    Plasma citrulline was measured as an assessment of enterocyte mass. Percent change in plasma citrulline from baseline at end of treatment was reported.


Secondary Outcome Measures :
  1. Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-Inf) of Teduglutide in Plasma [ Time Frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose ]
    Area under the concentration-time curve from time zero to infinity of teduglutide in plasma were evaluated.

  2. Area Under the Concentration-Time Curve From Time Zero to the Last Time Point (AUC0-t) of Teduglutide in Plasma [ Time Frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose ]
    Area under the concentration-time curve from time zero to the last time point of teduglutide in plasma were evaluated.

  3. Maximum Concentration (Cmax) of Teduglutide in Plasma [ Time Frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose ]
    Maximum concentration of teduglutide in plasma were evaluated.

  4. Time to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma [ Time Frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose ]
    Time to reach maximum observed drug concentration of teduglutide in plasma was evaluated.

  5. Terminal Half-Life (t1/2) of Teduglutide in Plasma [ Time Frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose ]
    Terminal half-life of teduglutide in plasma were evaluated.

  6. Apparent Clearance (CL/F) of Teduglutide in Plasma [ Time Frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose ]
    Apparent clearance of teduglutide in plasma were evaluated.

  7. Apparent Volume of Distribution (Vz/F) of Teduglutide in Plasma [ Time Frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose ]
    Apparent volume of distribution of teduglutide in plasma were evaluated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

This study has 3 stages, consisting of an optimization/stabilization period (Stage 1), a 24-week treatment period in which all patients will receive teduglutide (Stage 2), and a long-term extension (Stage 3).

During the long-term extension (Stage 3), patients will continue to receive teduglutide for up to an additional 24 months or until teduglutide is commercially available, whichever comes earlier.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02340819


Locations
Layout table for location information
Japan
Tohoku University Hospital
Sendai, Aoba-ku, Japan, 980-8574
Yokohama Municipal Citizen's Hospital
Yokohama, Hodogaya-ku, Japan, 240-8555
Hospital of Hyogo College of Medicine
Hyogo, Nishinomiya, Japan, 663-8501
Osaka University Hospital, Department of Gastroenterological Surgery
Osaka, Suita, Japan, 565-0871
Osaka University Hospital, Department of Pediatric Surgery
Osaka, Suita, Japan, 565-0871
Sponsors and Collaborators
Shire
Investigators
Layout table for investigator information
Study Director: Study Director Takeda
  Study Documents (Full-Text)

Documents provided by Takeda ( Shire ):
Study Protocol  [PDF] April 3, 2017
Statistical Analysis Plan  [PDF] October 29, 2018

Layout table for additonal information
Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT02340819    
Other Study ID Numbers: TED-C14-004
First Posted: January 19, 2015    Key Record Dates
Results First Posted: November 20, 2019
Last Update Posted: June 9, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, …)
Additional relevant MeSH terms:
Layout table for MeSH terms
Short Bowel Syndrome
Syndrome
Disease
Pathologic Processes
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Postoperative Complications
Teduglutide
Gastrointestinal Agents
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs